Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Urigen Pharmaceuticals has announced that the US Patent and Trademark Office issued a notice of allowance for claims for the first patent application for URG101, an investigational, bladder instillation for the treatment of painful bladder syndrome or interstitial cystitis.
Subscribe to our email newsletter
These claims broadly cover URG101 and its use in the treatment of painful bladder syndrome (PBS) by administering a glycosaminoglycan (such as heparin) and a local anesthetic.
Urigen recently closed a Phase II study of URG101 due to positive, statistically significant results at interim analysis with 50% patient enrollment. Based on these results, Urigen plans to advance the project into late-stage clinical development.
William Garner, Urigen’s president and CEO, said: “URG101 offers the potential to bring standardization to the treatment of PBS with the first FDA-approved product in a market conservatively estimated at $300-400 million annually in the US.”